Cancer reports最新文献

{"title":"One-Step Nucleic Acid Amplification Analysis of Sentinel Nodes in Endometrial Cancer Versus Ultrastaging: First Long-Term Follow-Up Data of Discordant Cases","authors":"Jan Kosťun,&nbsp;Khaled M. Ismail,&nbsp;Martin Pešta,&nbsp;Robert Slunečko,&nbsp;Petr Stráník,&nbsp;Vendula Smoligová,&nbsp;Jiří Presl","doi":"10.1002/cnr2.70082","DOIUrl":"10.1002/cnr2.70082","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Endometrial cancer (EC) is the most common gynecological cancer worldwide and its incidence is rising. The cornerstone of its management is surgical treatment with nodal staging. A monocentric study investigating the potential of the molecular biology method of one-step nucleic acid amplification (OSNA) in sentinel lymph node (SLN) analysis was conducted at our institution between April 2016 and January 2018. Histopathological ultrastaging was used as the reference standard for SLN examination and OSNA as the index test. The aim of this study was to assess the long-term outcome of patients with discordant SLN and OSNA results. To our knowledge, this is the first study exploring this issue.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Patients were followed in line with the current ESMO/ESGO/ESTRO recommendations. The institutional electronic database was retrospectively searched for patients' follow-up data from April 2016 till March 2023. Only patients who provided a written valid consent and had a positive OSNA and negative ultrastaging of their SLN analysis were included in the study. The primary endpoint was the retrospective analysis of their clinical outcome. Data from 58 patients enrolled into our previous study were reviewed and 12 discordant patients who met the inclusion criteria for this study were identified. The median follow-up was 83 months. Disease recurrence was detected in 3 (25%) patients, two of these were nodal and both patients died. One patient had a solitary lung metastasis which was surgically treated, and the patient was disease-free during the whole study period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The recurrence rate of patients included in the study was in the intermediate-high and high-risk group range, and hence, higher than expected based on ultrastaging results. Furthermore, benign epithelial inclusions do not seem to adversely affect OSNA SLN analysis in EC patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Incidence of Cancer Recorded in the Galapagos Archipelago","authors":"Stefano Nicolas Chisesi,&nbsp;Massimo Rugge,&nbsp;Giulia Raffaella Galli,&nbsp;Martina Manni,&nbsp;Veronica Mishell Luzuriaga Delgado,&nbsp;Teodoro Chisesi,&nbsp;Juan Carlos Ruiz,&nbsp;Rina Mariuxi Quinto Briones,&nbsp;Luisa Siculella,&nbsp;Stefano Guzzinati,&nbsp;Manuel Zorzi,&nbsp;Massimo Federico,&nbsp;Anna Iannone","doi":"10.1002/cnr2.70028","DOIUrl":"10.1002/cnr2.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer incidence in the Galapagos archipelago is unknown.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>In 2021, a task force including Ecuadorian and Italian researchers was established to estimate cancer incidence among the 25 244 Galapagos residents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Registration covered all malignancies, including malignant melanoma and non-melanoma skin cancers; case recording was based on the International Classification of Diseases for Oncology. The data collection involved an active search across all relevant health institutions on the islands and the mainland. Mortality data were obtained from the Ecuador national mortality registry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From January 2013 and December 2019, 174 new cancer cases were recorded, including 134 malignancies (M:F = 58:76) and 40 non-melanoma skin cancers. The mean age at diagnosis was 48 years for males and 56 years for females. Prostate, gastric, and melanocytic malignancies were most incident among males; breast, thyroid, and cervical cancers prevailed in females. The age-standardized incidence rates (ASR) were 80.39 for males and 99.24 for females with a mortality-to-incidence ratio 0.43. These ASRs were significantly lower than those reported in continental Ecuador and other South American countries.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This pilot cancer registration initiative in the Galapagos record a low incidence of malignancies and requires validation with temporal expansion of cancer registration. The environmental etiology of some of the most common cancers warrants strategic primary and secondary prevention efforts.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Incense Burning and the Risk of Lung Cancer in Asian Population: Meta-Analysis of Nine Case–Control Studies","authors":"Hui-Wen Tang,&nbsp;Fui-Ling Voon,&nbsp;Edmund Ui-Hang Sim","doi":"10.1002/cnr2.70095","DOIUrl":"10.1002/cnr2.70095","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Various studies have explored the potential association between incense burning and the risk of lung cancer. However, the findings from these studies have been inconsistent.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to provide a more comprehensive understanding of the relationship between incense burning and lung cancer risk in the Asian population through a meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This meta-analysis, which includes nine case–control studies conducted in Asia and identified through Google Scholar, PubMed, and ScienceDirect up to January 7, 2024, was performed to evaluate the relevant literature. Using a fixed-effects model, the pooled odds ratio (OR) was calculated to determine the overall association between incense burning and lung cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The results of the meta-analysis revealed a significant association between incense burning and the development of lung cancer (pooled OR = 1.33, 95% confidence interval [CI]: 1.20–1.48). Furthermore, a subgroup analysis was conducted based on smoking status. It was found that ever-smokers had a significantly higher risk of developing lung cancer when exposed to incense burning (pooled OR = 1.34, 95% CI: 1.09–1.65). Both hospital-based case–control studies (pooled OR = 1.28, 95% CI: 1.10–1.48) and population-based case–control studies (pooled OR = 1.39, 95% CI: 1.21–1.60) yielded significant associations between incense burning and lung cancer. Limitations of this study include the lack of detailed histologic information in most of the selected studies, highlighting the need for future research to include cohort studies that can more accurately assess the association between incense smoke inhalation and specific lung cancer subtypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, the findings of this meta-analysis, based on nine case–control studies, suggest that the risk of developing lung cancer among Asians may increase with exposure to incense burning.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CareHPV, Papanicolaou Positivity Status, and Their Association With Behavioral Risk Factors in Rural Women of Kamrup District, Assam, India","authors":"Pallavi Sarma,&nbsp;Debabrata Barmon,&nbsp;Avdhesh Kumar Rai,&nbsp;Amal Chandra Kataki,&nbsp;Anupam Sarma,&nbsp;Upasana Baruah,&nbsp;Lopamudra Kakoti,&nbsp;Debanjana Barman,&nbsp;Ratnadeep Sharma","doi":"10.1002/cnr2.70097","DOIUrl":"10.1002/cnr2.70097","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Screening of rural women of Assam by careHPV test for high-risk HPV (hr-HPV) DNA and Papanicolaou (PAP) test for abnormal cytology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>This prospective cross-sectional study included 480 non-pregnant women participants aged 20–70 years from Kamrup District, Assam. Two cervical scrap samples were obtained from eligible enrolled women. The Hr-HPV DNA test by CareHPV was performed with one cervical scrap, and a second cervical scrap sample was used for the Papanicolaou (PAP) test. The statistical analysis was done using RStudio for variables. A <i>p</i>-value &lt; 0.05 was considered to be statistically significant.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Women having positive hr-HPV DNA outcomes were 3.33% (16/480) and 7.7% (37/480) women had positive PAP. Tobacco chewing was significantly associated with positive hr-HPV DNA (<i>p</i> = 0.04) and positive PAP (<i>p</i> = 0.03) status. Alcohol-consuming women have a significantly higher risk of positive hr-HPV DNA (<i>p</i> &lt; 0.00001) and positive PAP (<i>p</i>-0.04) outcomes. Irregular menstruation (<i>p</i> = 0.004) and urogenital tract infection (<i>p</i> = 0.008) also have significant risk for a positive hr-HPV DNA status. The positive hr-HPV DNA status was also significant in women having &gt; 3 numbers of children birth (<i>p</i> = 0.003).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We found that the positive hr-HPV DNA status among rural women in Kamrup, Assam, was significantly associated with alcohol consumption, tobacco chewing, irregular menstruation, urogenital tract infection, and more than three children birth. The abnormal cytology outcome was also substantially associated with tobacco chewing and alcohol consumption.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodality Imaging Supports Cardiac Lesion Diagnosis in Patient With Liver Carcinoma: A Case Report","authors":"Hoa Thi Thuy Nguyen,&nbsp;Yen Thi Hai Nguyen,&nbsp;James N. Kirkpatrick,&nbsp;Viet Khoi Nguyen,&nbsp;Anh Van Nguyen,&nbsp;Hung Manh Pham,&nbsp;Walter Robert Taylor,&nbsp;Hoai Thi Thu Nguyen","doi":"10.1002/cnr2.70088","DOIUrl":"10.1002/cnr2.70088","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Nonbacterial thrombotic endocarditis (NBTE) is a rare cardiac manifestation in patients with advanced malignancies of the lungs, pancreas, gynecological system, and gastrointestinal tract. It is often confirmed postmortem by histopathological evidence of sterile platelet-fibrin deposits attached to the endocardium, most often on heart valves. To the best of our knowledge, our case is the first to report multiple heart lesions caused by the systemic effect of cholangiocarcinoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>We report the case of a 53-year-old male who presented with a stroke; extensive imaging studies, including transthoracic echocardiography (TTE), 2D/3D transesophageal echocardiography (TEE), cardiac multi-slice computed tomography, and cardiac magnetic resonance, found masses on the mitral valve, the aortic valve, and in the right ventricle, with the largest diameter 43 × 11 mm, which led to a diagnosis of NBTE secondary to presumed cholangiocarcinoma. Combining different echocardiography techniques, including TTE and TEE in specific clinical contexts, and training echocardiographers to improve TEE interpretation skills could be the most cost-effective option for early diagnosis, particularly in limited-resource settings, where advanced imaging modalities are not widely applicable.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>NBTE can manifest in patients with advanced cancer. A high index of clinical suspicion is of central importance for the diagnosis of NBTE, especially through an identification of the underlying predisposing conditions. A multi-disciplinary approach is crucial for NBTE optimal diagnosis and treatment. As in our patient, multimodality imaging plays a complementary role in clearly defining the nature of cardiac lesions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11666475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forced Vasohibin-1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity","authors":"Takahiro Koyanagi,&nbsp;Yasushi Saga,&nbsp;Yoshifumi Takahashi,&nbsp;Kohei Tamura,&nbsp;Suzuyo Takahashi,&nbsp;Akiyo Taneichi,&nbsp;Yuji Takei,&nbsp;Hiroaki Mizukami,&nbsp;Hiroyuki Fujiwara","doi":"10.1002/cnr2.70100","DOIUrl":"10.1002/cnr2.70100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Vasohibin-1 (VASH1), an angiogenic inhibitor, exhibits tubulin carboxypeptidase activity, which is involved in microtubule functions. Paclitaxel, the core chemotherapeutic agent for ovarian cancer chemotherapy, has a point of action on microtubules and may interact with VASH1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To examine the influence of VASH1 on intracellular tubulin detyrosination status, cyclin B1 expression, and paclitaxel chemosensitivity using VASH1-overexpressing ovarian cancer cell lines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Gene-transfected human ovarian cancer cell lines were subjected to western blot analysis. Western blot analysis of VASH1-overexpressing ovarian cancer cells revealed upregulated expression of detyrosinated tubulin and cyclin B1 compared with control cells. By WST-1 assay, paclitaxel chemosensitivity of VASH1-overexpressing ovarian cancer cells was markedly enhanced compared with that of control cells, whereas there was no significant difference in chemosensitivity to cisplatin. The forced expression of VASH1 enhanced tubulin carboxypeptidase activity and increased cyclin B1 expression, resulting in augmented paclitaxel chemosensitivity in ovarian cancer cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Ovarian cancer treatment strategies targeting VASH1 can potentiate the effects of conventional chemotherapy by inhibiting angiogenesis and regulating microtubule activity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Fibrolamellar Hepatocellular Carcinoma in Which Tumor Control Was Achieved by Re-Administering Atezolizumab and Bevacizumab","authors":"Satoru Hagiwara,&nbsp;Itsuki Oda,&nbsp;Kazuomi Ueshima,&nbsp;Yoriaki Komeda,&nbsp;Naoshi Nishida,&nbsp;Akihiro Yoshida,&nbsp;Tomoki Yamamoto,&nbsp;Naoya Omaru,&nbsp;Takuya Matsubara,&nbsp;Masatoshi Kudo","doi":"10.1002/cnr2.70090","DOIUrl":"https://doi.org/10.1002/cnr2.70090","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Fibrolamellar hepatocellular carcinoma (FL-HCC) clinically occurs in young people aged 20–30 years, who often have a normal liver background. We propose a treatment for such cases in which a combination therapy of atezolizumab and bevacizumab is followed by sandwiching radiation therapy to release tumor antigens and then re-administering the combination therapy of atezolizumab and bevacizumab (ABC conversion therapy).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>The patient is a 15-year-old girl. On April 18, 2022, she noticed skin yellowing and visited her local doctor. Computed tomography (CT) revealed a large mass in the right lobe of the liver and bile duct obstruction due to the tumor. She also had a nodule on her chest that appeared to be a metastatic tumor and was referred to Kinki University Hospital in April 2023. She was suspected to have FL-HCC based on contrast-enhanced ultrasound and CT scan results. There were findings suggestive of lung metastasis; however, she underwent a right hepatic lobectomy on May 17, 2023, considering the risk of liver failure and intra-abdominal bleeding due to the large liver tumor. A CT scan conducted on July 25, 2022, showing increased lung metastases, and she started atezolizumab/bevacizumab combination treatment on October 20, 2022. On March 15, 2023, multiple lung metastases and new intrahepatic lesions appeared, which was diagnosed as progressive disease (PD), and lenvatinib was discontinued. On November 17, 2023, radiation therapy (25 Gy/5 Fr) was administered to the lung and intrahepatic lesions to release tumor antigens, and on November 27, 2023, atezolizumab and bevacizumab combination treatment was resumed to control the tumor.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Combination therapy with atezolizumab, bevacizumab, and radiation therapy may be an option for the treatment of FL-HCC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142861650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Challenges due to a Germline Missense MSH2 Variant in a Patient With Immunotherapy-Responsive Locally Advanced Rectal Adenocarcinoma","authors":"Gertruda Evaristo,&nbsp;Carla Harmath,&nbsp;Jeremy P. Segal,&nbsp;Ardaman Shergill,&nbsp;Namrata Setia","doi":"10.1002/cnr2.70037","DOIUrl":"10.1002/cnr2.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Rapid and accurate identification of mismatch repair (MMR) deficiency and Lynch syndrome is critical in the prognostication and clinical management of patients with colorectal carcinoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Description</h3>\u0000 \u0000 <p>We describe here a young woman who developed a locally aggressive rectal adenocarcinoma with intact MMR protein expression by immunohistochemistry and absence of histologic evidence of MMR deficiency-associated increased tumoral immune response. Germline DNA-targeted sequencing identified <i>MSH2</i> variant p.R711P, initially classified as a variant of undetermined significance. Somatic tumoral DNA analysis revealed the identical <i>MSH2</i> variant, high tumor mutational burden, and microsatellite instability, in addition to superimposed alterations in <i>β2-microglobulin</i> gene, possibly explaining the altered intratumoral immunity. Consequently, the patient was started on immunotherapy, leading to successful disease control (33 month follow-up).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings emphasize the utility of an integrative approach in the assessment of MMR status for determining candidacy for immunotherapy, especially in the setting of missense variants in MMR genes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany","authors":"Nikolaj Rischke,&nbsp;Josephine Kanbach,&nbsp;Ulrike Haug","doi":"10.1002/cnr2.70060","DOIUrl":"https://doi.org/10.1002/cnr2.70060","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is a lack of real-world data on the use of targeted cancer drugs requiring molecular tumor diagnostics in the treatment of lung cancer in Germany.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We aimed to characterize the use of such drugs in lung cancer patients based on longitudinal analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Using the GePaRD database (claims data from ~20% of the German population) we identified lung cancer patients diagnosed in 2016 based on a previously developed algorithm and followed them until death, end of continuous insurance, or end of 2019. We determined the proportion of patients treated with at least one of the drugs under study (EGFR, ALK, and BRAF inhibitors). We described these patients regarding demographic characteristics, treatment patterns, and overall survival. We included 7833 incident lung cancer patients. Of these, 392 (5%) were treated with one of the drugs under study, the majority (62%) being female. In 314 out of the 392 patients (80%), the first dispensation was an EGFR inhibitor (afatinib: 54%, erlotinib: 33%), and in 72 patients (18%), it was an ALK inhibitor (crizotinib: 90%). The proportion of patients treated with these drugs was 4.8% in West Germany and 6.2% in East Germany. About half of these patients had chemotherapy before targeted therapy. Median overall survival after the first targeted therapy was 22 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>One twentieth of lung cancer patients diagnosed in 2016 in Germany received at least one EGFR, ALK, or BRAF inhibitor during follow-up. The proportion was higher in East than in West Germany. As the development and availability of new cancer drugs is a dynamic area, regularly updated utilization studies—ideally as cross-country-comparisons—are required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142851375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Giant Bilateral Wolffian Adnexal Tumor","authors":"Ling Huang,&nbsp;Yan Zhou,&nbsp;Xiaoshan Hong,&nbsp;Xiping Luo,&nbsp;Min Shen,&nbsp;Shanshan Yan,&nbsp;Xiaoli Sun","doi":"10.1002/cnr2.70084","DOIUrl":"10.1002/cnr2.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Wolffian adnexal tumor is a rare type of tumor that was first discovered and reported by Karim-inejad in 1973. Wolffian adnexal tumor lacks specific clinical manifestations and its histological morphology is similar to various other tumors, making it highly prone to misdiagnosis. To enhance our understanding of this disease, we hereby report a case of Wolffian adnexal tumor diagnosed and treated in our hospital.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>It is the first report of a giant bilateral Wolffian tumor, with pleural effusion and pericardial effusion as the initial symptoms. Magnetic resonance imaging (MRI) suggested a huge lobulated mass (25.3 × 17.8 × 21.9 cm) in the mid-lower abdomen and pelvis, involving both ovaries. A diagnosis of “ovarian malignancy” was made before the surgery. Hysterectomy, bilateral adnexectomy, and omentectomy were performed. Postoperative pathology revealed a bilateral Wolffian tumor. Postoperative chemotherapy with a taxol and cisplatin (TP) regimen was administered for six cycles. Follow-up at 2 months postoperatively showed resolution of pericardial and pleural effusions, and there has been no recurrence during the 3-year follow-up period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Wolffian adnexal tumor lacks specific clinical manifestations, and its prognosis is good after treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 12","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}